Weight reduction of 19.2%! Hengrui Medicine (01276) disclosed positive top-line results of the Phase III weight reduction study of GLP-1/GIP dual receptor agonist HRS9531 in China.

According to the Wisdom Financial APP, on July 15, 2025, Hengrui Medicine (01276) and American company Kailera Therapeutics jointly announced that the III phase clinical trial of GLP-1/GIP dual receptor agonist HRS9531 injection for the treatment of Chinese obese or overweight subjects (HRS9531-301) has achieved positive top-line results. Compared with placebo, all dosage groups of HRS9531 (2 mg, 4 mg, 6 mg) achieved superiority in both the primary and all key secondary endpoints. Hengrui Medicine plans to submit a new drug application (NDA) for HRS9531 injection for long-term weight management in China, while Kailera is advancing global clinical development of HRS9531 (KAI-9531).